GLP-1 and Semaglutide: Are They Really the Same Thing?

The biggest misconception: 'GLP-1' is not a medicine

Most people arriving at this question assume that GLP-1 is a drug name, or at least a shorthand for semaglutide specifically. Neither is true. GLP-1 is glucagon-like peptide-1, a hormone secreted by cells in your small intestine in response to food. It slows how quickly your stomach empties, prompts the pancreas to release insulin, and sends fullness signals to the brain. The effect is real but brief: your body breaks down natural GLP-1 within a couple of minutes.

The medicines now widely discussed for weight management are GLP-1 receptor agonists. They bind to the same receptor the natural hormone targets, but they are engineered to resist that rapid breakdown, giving a sustained effect over days or a week. Semaglutide is one such agonist. Liraglutide is another. Tirzepatide, the active ingredient in Mounjaro, adds a second receptor (GIP) to semaglutide's single-receptor approach. If you are wondering whether semaglutide and GLP-1 are the same thing, the short answer is that semaglutide mimics GLP-1 but the two are not interchangeable terms. When someone says 'I'm on a GLP-1', they usually mean one of these medicines, but the class is broader than any single drug.

Understanding this distinction matters practically. If you read a headline about 'GLP-1 results' and the underlying trial used tirzepatide, those figures do not apply directly to semaglutide, and vice versa. The NHS patient information for semaglutide covers its specific profile, not the whole receptor class.

Is semaglutide the same as Wegovy? And what about Ozempic?

Semaglutide is the active ingredient in several branded medicines, each licensed for a different purpose. Wegovy (injection) is semaglutide 2.4mg, licensed in the UK for weight management. Ozempic is semaglutide at lower doses, licensed for type 2 diabetes. Rybelsus is oral semaglutide, also licensed only for diabetes. And as of 11 June 2026, the MHRA approved Wegovy as the first oral GLP-1 medicine licensed in the UK specifically for weight management, the UK was the first country in Europe to grant this approval.

So asking whether semaglutide is the same as Wegovy has a nuanced answer: Wegovy contains semaglutide, but semaglutide is not only Wegovy. The licence (and the dose) is what determines what a medicine can lawfully be prescribed for. Prescribing Ozempic off-label for weight loss is not the same as prescribing Wegovy; they carry different licensed indications and different prescriber responsibilities. This is not a technicality. It is the regulatory foundation on which safe prescribing sits.

You can read more about Wegovy's licensed uses and its evidence base if you want to go deeper on the injection form specifically.

How semaglutide fits alongside other GLP-1 medicines licensed for weight loss in the UK

Semaglutide (Wegovy injection, or the newer Wegovy tablet) and tirzepatide (Mounjaro) are the two GLP-1-pathway medicines currently licensed in the UK for weight management. Saxenda, based on liraglutide, holds a licence too but works on the same single GLP-1 receptor at a lower potency and requires a daily injection rather than a weekly one.

Tirzepatide's additional GIP mechanism makes it the only dual agonist in this space. The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, compared tirzepatide directly with semaglutide 2.4mg over 72 weeks and found tirzepatide produced a greater average weight reduction. That head-to-head result is useful context, though which medicine suits a specific person depends on their medical history, tolerability, and other factors a prescriber weighs individually. The full semaglutide overview on this site covers the trial evidence in more detail.

For context on what private treatment typically costs and what to look for in a legitimate provider, our weight-loss treatment overview sets out the landscape plainly. If you want the full comparison of the two licensed injectable options, the GLP-1 and semaglutide relationship page covers the pharmacology side by side. Thinking about which route might suit you is best done with a prescriber who can look at your health history rather than a search result.

What this means if you are considering treatment

The term 'GLP-1' has become a cultural shorthand for a whole category of medicines, which can make it hard to know which specific drug is being discussed, what it is licensed for, and whether the results you have read about apply to the product your prescriber might consider. That confusion is worth clearing up before starting a conversation about treatment.

A few practical things to know. Wegovy (both the injection and the tablet) and Mounjaro are prescription-only medicines in the UK. No route to them is legal without a clinical assessment and a valid prescription from a registered prescriber. The assessment covers your BMI, any weight-related conditions, your current medicines, and your medical history. A prescriber registered with the General Pharmaceutical Council reviews every consultation at nume, every one, not a batch process, and not software.

For those curious about how the newer oral option differs from the weekly injection, the tablet sits in the fridge-free zone of your daily routine, taken first thing in the morning before the kettle is on, with a small amount of plain water, before any food or drink. That practical difference matters to some people more than the pharmacology does. If you would like a prescriber to help you make sense of which option, if any, is appropriate for you, the consultation is free and reviewed the same working day. Speak to our prescribers to get started.